As an increasing number of pharmaceutical companies experiment with different ways to cut costs while boosting productivity amid the pandemic, the industry is increasingly switching to cloud-based technologies. In this scenario, Veeva has become indispensable for the life sciences industry, helping life sciences enterprises manage customer databases, track drug developments, and organize clinical trials.
Veeva entered the life sciences market with its Commercial Cloud business, including the core Customer Relationship Management (CRM) offering, which has now transitioned into a mature product with a market share of about 80% across all global pharmaceutical companies. Lately, Veeva has been experiencing increasing demand for its Development Cloud (R&D) suite, which now drives more than half of its total revenue.
This report focuses on changing market dynamics, emerging service provider trends, and guidance on devising the right market entry strategy for Veeva services
Scope
Industry: life sciences
Services: Veeva services
Geography: global
Contents
This report comprises three sections, each containing insights on the Veeva services market:
Veeva Systems’ product performance and future growth outlook
Veeva services market size and insights on service providers
The right market entry strategy for the Veeva services market
The pandemic highlighted the need for increased virtual and digital interactions between life sciences enterprises and customers. Enterprises realized that life sciences-specific Customer Relationship Management (CRM) systems were not inherently equi…
